The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Prognostic Significance of Extent of Disease in Bone in Patients With Androgen-Independent Prostate Cancer
Abstract
PURPOSE: To evaluate the prognostic significance of a bone scan index (BSI) based on the weighted proportion of tumor involvement in individual bones, in relation to other factors and to survival in patients with androgen-independent prostate cancer. PATIENTS AND METHODS: Baseline radionuclide bone scans were reviewed in 191 assessable patients with androgen-independent disease who were enrolled onto an open, randomized trial of liarozole versus prednisone. The extent of skeletal involvement was assessed by scoring each scan using the BSI and independently according to the number of metastatic lesions. The relationship of the scored bone involvement to other known prognostic factors was explored in single- and multiple-variable analyses. RESULTS: In single-variable analyses, the pretreatment factors found to be associated with survival were age (P = .0446), performance status (P = .0005), baseline prostate-specific antigen (P = .0001), hemoglobin (P = .0001), alkaline phosphatase (P = .0002), AST (P = .0021), lactate dehydrogenase (P = .0001), and treatment (P = .0098). The extent of osseous disease was significant using both the BSI (P = .0001) and the number of lesions present (P = .0001). In multiple-variable proportional hazards analyses, only BSI, age, hemoglobin, lactate dehydrogenase, and treatment arm were associated with survival. When the patient population was divided into three equal groups, with BSI values of < 1.4%, 1.4% to 5.1%, and > 5.1%, median survivals of 18.3, 15.5, and 8.1 months, respectively, were observed (P = .0079). CONCLUSION: The BSI quantifies the extent of skeletal involvement by tumor. It allows the identification of patients with distinct prognoses for stratification in clinical trials. Further study is needed to assess the utility of serial BSI determinations in monitoring treatment effects. The BSI may be particularly useful in the evaluation of agents for which prostate-specific antigen changes do not reflect clinical outcomes accurately.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma
Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., & Goodman, P. J. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908173210702 · Cited by 1,464
Cited by
Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity
Coleman, R. E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0931 · Cited by 2,488
Scher, H. I., Morris, M. J., Stadler, W. M., Higano, C., Basch, E., Fizazi, K., Antonarakis, E. S., Beer, T. M., Carducci, M. A., Chi, K. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2702 · Cited by 1,654
Self-citationImaging biomarker roadmap for cancer studies
O'Connor, J. P. B., Aboagye, E. O., Adams, J. E., Aerts, H. J. W. L., Barrington, S. F., Beer, A. J., Boellaard, R., Bohndiek, S. E., Brady, M., Brown, G., et al. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.162 · Cited by 1,091
Tu, S.-M., Millikan, R. E., Mengistu, B., Delpassand, E. S., Amato, R. J., Pagliaro, L. C., Daliani, D., Papandreou, C. N., Smith, T. L., Kim, J., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03639-4 · Cited by 396
Smaletz, O., Scher, H. I., Small, E. J., Verbel, D. A., McMillan, A., Regan, K., Kelly, W. K., & Kattan, M. W. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.021 · Cited by 386
Self-citation
Metadata
- Authors
- Sabbatini, P., Larson, S. M., Kremer, A., Zhang, Z.-F., Sun, M., Yeung, H., Imbriaco, M., Horak, I., Conolly, M., Ding, C., Ouyang, P., Kelly, W. K., & Scher, H. I.
- Venue
- Journal of Clinical Oncology
- Published
- 1999-03
- Volume
- 17
- Issue
- 3
- Pages
- 948-948
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1705165894
- Cited by
- 237
- References
- 2
- FWCI
- 5.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prognostic Significance of Extent of Disease in Bone in Patients With Androgen-Independent Prostate Cancer. https://app.cochat.ai/papers/10.1200/jco.1999.17.3.948
- The paper
- Sabbatini, P., Larson, S. M., Kremer, A., Zhang, Z.-F., Sun, M., Yeung, H., Imbriaco, M., Horak, I., Conolly, M., Ding, C., Ouyang, P., Kelly, W. K., & Scher, H. I. (1999). Prognostic Significance of Extent of Disease in Bone in Patients With Androgen-Independent Prostate Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1999.17.3.948
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.